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Abstract
Background: Primary tumor recurrence commonly occurs after surgical resection of lung squamous cell carcinoma (SCC).
Little is known about the genes driving SCC recurrence.
Methods: We used array comparative genomic hybridization (aCGH) to identify genes affected by copy number alterations
that may be involved in SCC recurrence. Training and test sets of resected primary lung SCC were assembled. aCGH was
used to determine genomic copy number in a training set of 62 primary lung SCCs (28 with recurrence and 34 with no
evidence of recurrence) and the altered copy number of candidate genes was confirmed by quantitative PCR (qPCR). An
independent test set of 72 primary lung SCCs (20 with recurrence and 52 with no evidence of recurrence) was used for
biological validation. mRNA expression of candidate genes was studied using qRT-PCR. Candidate gene promoter
methylation was evaluated using methylation microarrays and Sequenom EpiTYPER analysis.
Results: 18q22.3 loss was identified by aCGH as being significantly associated with recurrence (p=0.038). Seven genes
within 18q22.3 had aCGH copy number loss associated with recurrence but only SOCS6 copy number was both technically
replicated by qPCR and biologically validated in the test set. SOCS6 copy number loss correlated with reduced mRNA
expression in the study samples and in the samples with copy number loss, there was a trend for increased methylation,
albeit non-significant. Overall survival was significantly poorer in patients with SOCS6 loss compared to patients without
SOCS6 loss in both the training (30 vs. 43 months, p=0.023) and test set (27 vs. 43 months, p=0.010).
Conclusion: Reduced copy number and mRNA expression of SOCS6 are associated with disease recurrence in primary lung
SCC and may be useful prognostic biomarkers.
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Introduction
Lung cancer is the leading cause of cancer-related mortality
worldwide, accounting for greater than one million deaths
annually [1]. Non-small cell lung cancer (NSCLC) accounts for
80% of all lung cancer diagnoses. Conventionally NSCLC has
been divided into three subtypes: adenocarcinoma (AC), squamous
cell carcinoma (SCC) and large cell carcinoma (LC), with AC and
SCC accounting for 85% of NSCLC cases [2]. The treatments for
NSCLC have been generic and largely ineffective resulting in a
five-year survival of 15% [3]. Early diagnosis followed by surgical
resection remains the most effective treatment strategy [4].
However, even in stage I patients undergoing surgical resection,
recurrence of the primary tumor occurs in 30–35% of cases [2].
Molecular alterations are likely to be involved in driving disease
recurrence, but the specific genes involved remain to be
elucidated.
DNA copy number alterations are ubiquitous to almost all
human malignancies [5]. The identification of tumor-specific
DNA copy number alterations can assist in the discovery of
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30398oncogenes or tumor suppressor genes which are typically located
within genomic regions of amplifications or loss respectively [5].
Array-comparative genomic hybridization (aCGH) has been used
to investigate copy number alterations in several malignancies,
including lung SCC [6,7,8,9,10,11,12,13,14,15,16]. Karyotyping
and conventional CGH characterized lung SCCs, as having
frequent copy number gains in 1p, 3q, 5p, 7q and 8q and copy
number loss in 3p, 5q, 8p, 9p, and 14q [13,17,18,19,20,21,22].
High-resolution copy number characterization of these regions
resulted in the discovery of the driver oncogenes SOX2 [14] and
FGFR1 [23]. To our knowledge, the few studies that have
specifically evaluated genomic differences unique to lung SCC
recurrence and/or metastases have used low-resolution platforms
on relatively small sample sizes [18,24]. Consequently, while these
studies have identified genomic regions with copy number
alterations associated with recurrence and/or metastases, they
have not been able to identify the driving gene/s associated with
recurrence.
In this study we analyzed lung SCC tumors using a whole-
genome aCGH microarray platform to identify genomic copy
number alterations specific to tumors, which developed early
recurrence of primary tumor post-resection. To identify recur-
rence specific genes within the candidate genomic regions, we used
an independent method of copy number determination (quanti-
tative PCR) and confirmed the findings in an independent set of
SCC tumors. Finally, to assess whether candidate gene/s copy
number alterations have prognostic value, we analyzed the
survival data of training and test set subjects.
Materials and Methods
Subjects and Tumor Samples
The training set consisted of sixty-two tumor samples, which
were collected from patients with histologically proven primary
lung SCC. The tumor samples were obtained from patients who
underwent curative-intent surgical resection at The Prince Charles
Hospital between 1990 and 2004. Formalin fixed paraffin
embedded tissue samples of normal lung and tumor tissue,
adjacent to the frozen tumor sample, was used for hematoxylin
and eosin examination and only those tumor samples that
contained at least 50% tumor cells and all surgical bronchial
margins were free of disease were used as training set samples and
underwent aCGH experiments. The subjects were fitted to one of
our two disease recurrence outcome criteria: non-recurrence,
clinically disease-free for at least 36 months following surgery; or
recurrent disease, unambiguous clinical, imaging, or histopatho-
logic evidence of local or distant recurrence of the original primary
lung cancer in a local or distant metastatic site occurring between
3 and 18 months post-resection. The threshold of 36 months for
non-recurrence cases was selected since most patients develop
disease recurrence within this period of time and to allow for
comparison with other similarly designed studies. In addition, an
independent test set, consisting of seventy-two tumor samples that
were collected and stored in The Prince Charles Hospital Lung
Tissue Bank were utilized for validation purposes. Inclusion and
exclusion criteria for the test set were identical to that used for the
training set.
Ethics Statement
Ethics approval was granted from TPCH Human Research
Ethics Committee (HREC/09/QPCH/17) and The University
of Queensland (Project number: 2009000727) and all subjects
provided written informed consent prior to inclusion in the
study.
Nucleic Acid Extraction
Tumor and paired normal lung tissue collected from surgical
resection specimens, as previously described [25], were snap
frozen and processed for genomic DNA and total RNA extraction.
A total of 300–500 mg of frozen tissue was used for genomic DNA
extraction using a modified salt-precipitation method [26]. High
molecular weight genomic DNA was purified using a Blood and
Cell Culture mini kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. Purified genomic DNA was quanti-
tated with a NanoDrop spectrophotometry system (NanoDrop
Technologies, Wilmington, DE, USA) using 2 mL of DNA. Total
RNA was extracted as described previously [25].
Array Comparative Genomic Hybridization
aCGH experiments were performed on Human Genome
Microarray 44B (Agilent Technologies Inc.) microarrays, a high-
resolution 60-mer oligonucleotide-based microarray that contains
42,920 probes sourced from the NCBI human genome reference
sequence. These probes represent 24,983 genes. Microarray
images were analyzed using Feature Extraction Software, version
8.0 (Agilent Technologies, Inc.) and assessed for relative data
quality in CGH Analytics, version 3.4.27 (Agilent Technologies,
Inc.). For each aCGH microarray, a tumor sample (test) was
compared with a commercially available Female Genomic DNA
(Promega, Madison, USA). A triangular smoothing algorithm with
a moving average window of 2 Mb was applied to log ratio aCGH
data. aCGH microarray experiments were designed in compliance
with the MIAME guidelines (http://www.mged.org/Work-
groups/MIAME/miame.html). The aCGH raw data (unchanged),
metadata and clinical information of the subjects in this study have
been deposited in the NCBI Gene Expression Omnibus (GEO)
public repository (http://www.ncbi.nlm.nih.gov/ geo) and can be
accessed through the accession number GSE32058. Normalized
aCGH data was analyzed using Genomic Identification of
Significant Target in Cancer (GISTIC), a bioinformatics method
that identifies genomic regions most likely to contain oncogenes
and tumor suppressor genes [27]. Segmented regions were
estimated with Circular Binary Segmentation (CBS) using the R
package ‘‘DNACopy’’ (http://www.r-project.org/). Copy number
variation data from the Human Genome Build 35 (hg17) was
obtained from the Database of Genomic Variants (DGV, http://
projects.tcag.ca/variation). GISTIC scores for locus (G score) were
obtained as the product of frequency and mean amplitude of
amplifications or deletions. Only amplifications exceeding a log2
copy number ratio of 0.848 for amplifications or below 0.737 for
deletions were included, accounting for 2.8 copies per cell and 1.6
copies per cell in samples respectively. G scores were compared
against a null model to determine a false discovery rate (q value)
and peaks with q values below 0.05 were considered.
Real-time Quantitative PCR and Quantitative Reverse
Transcription PCR
To validate copy number alterations detected by aCGH, real-
time quantitative PCR (qPCR) assays were used. Pre-designed
QuantiTect primers (Qiagen) were used to measure candidate
gene copy number by qPCR, details of which are provided in
Table S3. Information pertaining to the location of the primers
was obtained from Qiagen (http://www.qiagen.com/geneglobe).
b-actin was used as the reference locus for qPCR. Normal human
pooled genomic DNA was used as reference DNA (Promega,
Madison, USA). All qPCR experiments were performed using the
Rotor-Gene 6000
TM (Qiagen, Hilden, Germany). Each assay was
performed in triplicate in 10 mL reactions containing 5 mL
SOCS6 in Lung Squamous Cell Carcinoma
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QuantiTect Primer assay (106; Qiagen); and 10 ng of genomic
DNA. PCR product amplification was performed according to the
following conditions: 1 cycle at 95uC for 10 minutes, 40 cycles, of
95uC for 10 seconds and 60uC for 30 seconds.
To evaluate the mRNA expression levels of candidate genes, we
used qRT-PCR. mRNA levels of the candidate gene were
compared to those of housekeeper genes. The geometric mean
of the relative gene expression of BAT1, SEPT2 and 18s were used
as the comparator reference for RT-PCR. Relative gene
expression was calculated using the Pfaffl method [28]. qRT-
PCR was carried out using QuantiTect primer sets and 30 ng of
cDNA as template. All assays were performed in triplicate in
10 mL reactions containing 5 mL QuantiFast SYBR Green PCR
Master Mix (26; Qiagen) and 2 ul QuantiTect Primer assay (106;
Qiagen).
Methylation Analysis
Microarray. Methylation microarray data (manuscript in
preparation) was available for 49 tumor samples from the training
set. Genomic DNA was bisulphite converted using an EZ DNA
Methylation Kit (Zymo Research, CA, USA) and hybridized to
Illumina Infinium Methylation 27 V1.0 microarrays. The b-value
was determined as the ratio of methylated fluorescence signal to
the combined signal of the methylated and unmethylated alleles,
giving a value between 0 and 1.
MassARRAY H EpiTYPER. We employed the MassARRAYH
EpiTYPER analysis (Sequenom), for the detection and quantitation
of DNA methylation of the promoter regions of SOCS6.T h e
EpiTYPER Sequenom Mass Array service was provided by
Sequenom, Inc. (Brisbane, Australia) and for each sample, 1.5 mg
of DNA in a volume of 30 mL was sent to the service. EpiTYPER is a
validated approach in providing a highly quantitative view of CpG
dinucleotide methylation, with up to single nucleotide resolution,
using the technique of MALDI TOF (Matrix-assisted laser
desorption/ionization Time of Flight) mass spectrometry. Primers
for SOCS6 were designed using the Epidesigner software (primers
available on request). The SOCS6 promoter was divided into one or
moreamplicons, within a region comprising 2500 bp upstream of the
transcription start site and the regions analyzed corresponded to
annotated CpG islands identified using the UCSC Genome Browser
(http://genome.ucsc.edu). Genomic DNA was bisulfite treated using
EZ-96 DNA methylation kits (Zymo Research, CA, USA), followed
by PCR amplification using primers directed to the promoter regions
of SOCS6. Amplicons were then subjected to the EpiTYPER assays,
the products analyzed by mass spectrometry and methylation ratios
obtained using EpiTYPER v1.0.5 software (SEQUENOM). The
relative amount of methylation (% methylation) was determined by
comparing the signal intensities between the mass signals of
methylated and non-methylated template.
Statistical Analysis
All statistical analyses were performed using SPSS (Version 17,
SPSS Inc., Chicago, USA). Fisher’s exact test was applied to assess
the relationship between copy number as a bivariate categorical
variable (above or below the log base 2 threshold) and clinico-
Table 1. Subject Characteristics.
Training set Test set
Recurrence
SCC, n (%)
Non-Recurrence
SCC, n (%) p-value*
Recurrence
SCC, n(%)
Non-Recurrence
SCC, n(%) p-value*
Subjects, n 28 34 20 52
Age, years
Median (range) 67 (39–81) 69 (44–84) 69 (39–82) 69 (44–91)
Gender, n(%)
Males 21 (75) 25 (73) 1.0 14 (70) 43 (83) 0.33
Females 7 (25) 9 (27) 6 (30) 9 (17)
Smoking history, n(%)
Never 3 (11) 1 (3) 0.32 2 (10) 4 (7) 0.67
Ever smokers 25 (89) 33 (97) 18 (90) 48 (93)
Pack years, median (range) 35 (0–100) 38 (0–135) 39 (0–75) 35 (0–243)
Stage, n(%)
I–II 23 (82) 30 (88) 0.72 14 (70) 44 (85) 0.19
III–IV 5 (18) 4 (12) 6 (30) 8 (15)
Tumor differentiation, n(%)
Well to moderate 14 (50) 18 (53) 1.0 9 (45) 26 (50) 0.80
Poor 14 (50) 16 (47) 11 (55) 26 (50)
Tumor invasion, n(%)
Lymphatic 8 (29) 4 (12) 0.12 2 (10) 5 (10) 1.00
Vascular 11 (39) 8 (24) 0.27 10 (50) 15 (29) 0.10
Perineural 3 (11) 0 (0) 0.09 2 (10) 4 (8) 0.67
Pleural 6 (21) 8 (24) 1.00 5 (33) 16 (31) 0.78
*p-value determined using Fisher’s exact test.
doi:10.1371/journal.pone.0030398.t001
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to measure differences in candidate gene copy number between
recurrence and non-recurrence samples. The censored five-year
overall survival after surgical resection was estimated using the
Kaplan-Meier method and survival differences were analyzed
using the log-rank test.
Results
aCGH Profile of Lung SCC Tumors and Recurrence
Phenotype
In the training and test set subjects, there were no significant
differences in clinical or pathological characteristics between those
with disease recurrence and those without (Table 1).
Weinitiallyassayedcopynumberalterationsinall62tumorsofthe
training set. GISTIC identified nineteen genomic regions (thirteen
deletions and six amplifications) with a false discovery rate ,0.05
(Figure 1) (Table 2). The frequency of copy number alteration at each
of these regions was compared between disease recurrence groups.
Only 18q22.3 was significantly different, showing more frequent loss
in recurrence compared with non-recurrence tumors (54% vs. 24%,
p=0.038) (Table 3). When the tumors were stratified by recurrence
phenotype and analyzed separately, GISTIC identified loss of
18q22.3 only in tumors, which recurred, while loss in 1p, 3p, 4q,
5q, 8p, 9p, 10q, 13q, 16q, 17p were common to both phenotypes.
Conversely, amplifications in 5p15.33, 8q24.21, 9p21.1 and 19q13.2
were unique to non-recurrence tumors while amplifications in 3q and
8p occurred in both phenotypes (Table S1).
Candidate Genes within Recurrence-Associated Copy
Number Loss at 18q22.3
The GISTIC algorithm identified a region of loss within
18q22.3 from 64017241 to 75522477 (Table 2). Within 18q22.3
were 18 candidate genes (Table S2), which were further studied
to determine whether they were recurrence-specific. Seven of
these (CYB5A, SOCS6, DOK6, C18orf55, CCDC102B, NETO1 and
RTTN) had lower copy number in primary tumors of patients
that recurred (Figure 2). Table S2 lists the oligonucleotide probe
ID and location for all probes within the 18q22.3 region of
interest.
aCGH based copy number assessment of the seven candidate
genes was technically validated by qPCR (Figure 3). A high degree
of concordance between aCGH and qPCR data was observed for
SOCS6 (R
2=0.59, p,0.001), but CYB5A, DOK6, C18orf55,
CCDC102B, NETO1 and RTTN showed Pearson coefficients of
,0.5 (Figure 3). Given these results, we also tested the association
between qPCR-determined copy number in the training and test
set tumors. qPCR confirmed significantly lower SOCS6 copy
number in the group with tumor recurrence in both training
(p=0.023) (Figure 4A) and test (p=0.005) (Figure 4B) sets.
Figure 1. Genomic copy number alterations in lung squamous cell carcinomas. Plots of high-level amplifications (a) and deletions (b) in 62
lung SCCs from GISTIC analysis of aCGH data. X-axis shows the G score (top) and false discovery rate (q value; bottom) with a green line demarcating a
false discovery rate of 0.05. Labels on the right denote the peaks of the most significantly altered regions.
doi:10.1371/journal.pone.0030398.g001
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somatically acquired, SOCS6 copy number was determined by
qPCR in the paired normal lung of the training set tumors. The
median copy number of SOCS6 in normal lung was higher than in
tumor samples (p,0.001) (Figure S1A), and the number of SOCS6
copies in normal lung did not differ between patients with
recurrence and non-recurrence tumors (p=0.321) (Figure S1B).
SOCS6 mRNA Expression in SCC Tumors
To determine if SOCS6 DNA copy number was an important
regulator of mRNA expression, qRT-PCR was performed in the
training and test set tumor cDNA samples. There was a modest
correlation between SOCS6 copy number and mRNA expression
in the training set (r
2=0.396, p=0.004) (Figure 5A) and test set
(r
2=0.416, p,0.001) (Figure 5C). SOCS6 mRNA expression was
significantly lower in recurrence samples in the training (p=0.013,
Figure 5B) and test sets (p=,0.001, Figure 5D).
SOCS6 Methylation Status in SCC tumors
An alternative mechanism responsible for reduced mRNA
expression, in addition to gene copy number loss, is promoter
hypermethylation. We therefore evaluated the methylation status
of SOCS6 in the training set of SCC tumor samples using two
independent techniques: Illumina Infinium Methylation micro-
arrays and MassARRAYH EpiTYPER analysis. Methylation
microarray analysis of 30 non-recurrence and 19 recurrence
tumors from the training set found the methylation index (b) was
lower in tumors with SOCS6 loss (i.e. ,2 copies/cell) (n=29) than
in tumors with normal copy number (i.e. $2 copies/cell) (n=20),
but the difference was not statistically significant (0.04760.047 vs.
0.06360.041, p=0.211). There was no correlation between
SOCS6 methylation and mRNA expression either in samples with
,2 SOCS6 copies/cell (r
2=20.065, p=0.748) or in samples with
$2 SOCS6 copies/cell (r
2=0.061, p=0.810).
Quantitation of the degree of SOCS6 methylation using mass
spectrometry of amplification products with the Sequenom
EpiTYPER assay was performed in 62 SCC tumor samples from
the training set. Five primer sets were designed covering 95 CpG
dinucleotides within the promoter region upstream from the
transcription site. Thirty-two amplicons failed to provide any
analyzable data and another eight had unreliable results and were
excluded. The average methylation for the 62 samples across all 55
CpG sites was 9%. There was no difference in the levels of
methylation between recurrence and non-recurrence samples
(8.9% vs. 9%, p=0.966) and there was no difference between
methylation levels according to recurrence phenotype compared
to reference DNA (recurrence 8.9% vs. 12%, p=0.189; non-
recurrence 9% vs. 12%, p=0.137). As observed in the methylation
microarray data, there was a trend for negative correlation
between SOCS6 methylation and mRNA expression in the samples
with ,2 SOCS6 copies/cell (R
2=20.377, p=0.092) while this was
not the case in samples with $2 SOCS6 copies/cell (R
2=0.232,
p=0.210).
SOCS6 Loss and Decreased mRNA Expression was
Associated with Poor Survival in SCC tumors
Training and test subjects were deemed to have ‘SOCS6 loss’ if
their tumors had less than 1.45 copies/cell, as measured by qPCR.
Table 2. GISTIC Identified Chromosomal Regions with Copy Number Alterations in Training Set SCC Tumors.
Cytoband Broad or Focal Region Limits
Frequency of
deletions in test set
samples, n (%) FDR values
GISTIC genes
within region
Cancer-associated
genes
Regions with Copy Number Losses
9p21.3 Both 21733411–21957547 33 (53) 2.30610
218 4 CDKN2A, CDKN2B
8p23.1 Broad 3313385–12711819 40 (65) 1.04610
213 67 ANGPT2
3p12.1 Broad 84414538–85858393 38 (61) 1.04610
213 6 POU1F1
5q13.3 Broad 76066702–76539988 38 (61) 7.97610
213 76 PIK3R1, HTR1A
4q28.2 Broad 130278523–134426567 37 (60) 1.06610
211 12 PLK4
10q23.31 Broad 89540134–89615643 25 (40) 2.67610
209 4 PTEN
13q22.1 Broad 72396304–72490843 25 (40) 4.32610
209 7
1p21.1 Broad 101664084–102994090 30 (48) 2.41610
206 8 COL11A1
17p12 Broad 12394069–12459756 24 (39) 1.50610
204 17
4p15.31 Broad 20391110–20848036 35 (56) 4.09610
203 59 BST1, SLIT2, PI4K2B
16q23.3 Broad 80626349–81449546 23 (37) 1.03610
203 16
18q22.3 Broad 64017241–75522477 24 (39) 4.96610
203 18 SOCS6, CD226, RTTN,
MBP
11q25 Broad 132926079–134452384 17 (27) 2.83610
202 10 ACAD8
Regions with Copy Number Gains
3q26.33 Focal 183473858–183941579 15 (24) 1.38610
213 9 SOX2, TP73L
8p12 Focal 38703882–38796309 8 (13) 9.01610
209 2 FGFR1
19q13.2 Focal 43840068–44336812 4 (6) 2.73610
204 66 AKT2, ECH1
11q13.3 Focal 68821296–70110392 5 (8) 3.06610
202 13 CCND1, PPFIA1
5p15.33 Focal 1–1510601 6 (10) 1.46610
202 21 TERT
8p11.21 Focal 41969702–42416269 2 (3) 4.19610
202 630 TACC1
doi:10.1371/journal.pone.0030398.t002
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minus two standard deviations of the training set tumors with $2
copies/cell (aCGH-derived) (n=26) (SOCS6 mean copy number 6
standard deviation=2.0360.29). This approach has been previ-
ously used to determine qPCR thresholds for aCGH gene copy
number alterations [29].
Evaluation of overall survival at five years post surgery in the
training and test set subjects demonstrated that those with ‘SOCS6
loss’ had significantly worse survival compared to subjects without
‘SOCS6 loss’ (training set: 30 months vs. 43 months, Log-rank
p=0.023; test set: 27 months vs. 43 months, p=0.010) (Figure 6A
and 6C, respectively). Stratification by TNM stage found ‘SOCS6
loss’ was associated with worse survival in early stage (stage I–II)
tumors (training set: 28 months vs. 46 months, p=0.004;testset:
27 months vs. 45 months, p=0.038) (Figure 6B and 6D,
respectively) but not in the smaller cohort with advanced stage
disease (stage III–IV) (training set: 35 months vs. 22 months,
p=0.518 and test set: 26 months vs. 34 months, p=0.293,Figure
S2A and S2B respectively). ‘SOCS6 loss’ was also associated with
shorter recurrence free survival in both the training (28 months
vs. 46 months, Log-rank p=0.007) and test set subjects (28
months vs. 46 months, Log-rank p=0.019) (Figure S3A and S3B,
respectively).
Stratification of samples into low SOCS6 mRNA expression
(#0.85 relative mRNA expression) compared to normal SOCS6
mRNA expression (.0.85 relative mRNA expression), was
associated with worse overall survival (training set: 25 months vs.
44 months, p=0.002; test set: 31 months vs. 48 months, p=0.004)
(Figure S4A and S4C, respectively). In the subjects with early stage
tumors, decreased SOCS6 mRNA expression was associated with
worse overall survival (training set: 23 months vs. 46 months,
p,0.001; test set: 35 months vs. 48 months, p=0.033) (Figure S4B
and S4D, respectively). However, this was not demonstrable in the
small cohort with advanced stage tumors (training set: 28 months
vs. 29 months, p=0.973; test set: 12 months vs. 37 months,
p=0.101, Figure S2C and S2D respectively).
Discussion
Recent improvements in clinical outcome in NSCLC has been
achieved by using biologically targeted therapies, underpinning the
importance of recognizing the molecular heterogeneity of lung
cancer [30]. The tumor-node-metastasis (TNM) staging system
based on tumor size, nodal involvement and the presence of distant
metastases is the current standard for predicting prognosis in
NSCLC patients [31,32]. However, TNM stage cannot fully
encompass the heterogeneous biology of NSCLC tumors. In
primary lung SCC tumors with well-annotated recurrent disease
follow-up, we have tried to identify novel gene/s that may be
involved in the pathophysiology of tumor recurrence after surgical
resection. In this study,we found that lossof18q22.3occurredmore
often in primary tumors that recurred than those that did not.
Located within the 18q22.3 region is SOCS6, whose copy number
was significantly lower in recurrence tumors compared to the non-
recurrence tumors. We also found that DNA copy number loss and
that promoter methylation may not regulate SOCS6 mRNA
expression. Importantly, loss of SOCS6 copy number and reduced
mRNA expression had prognostic significance.
The loss of 18q11-23 is a well-recognized marker of poor
prognosis in many solid organ malignancies including esophageal
Table 3. Frequency of Copy Number Alterations of GISTIC Identified Chromosomal Regions in Recurrence and Non-recurrence SCC
Training Set Samples.
Cytoband Loss in SCC Recurrence, n (%) Loss in SCC Non-Recurrence, n (%) p-value*
Regions with Copy Number Losses
18q22.3 15 (54) 8 (24) 0.038
4q28.2 14 (50) 23 (68) 0.198
1p21.1 11 (39) 19 (56) 0.213
10q23.31 9 (32) 16 (47) 0.301
11q25 6 (21) 11 (32) 0.400
8p23.1 20 (71) 20 (59) 0.425
3p12.1 19 (68) 19 (56) 0.434
5q13.3 17 (61) 21 (62) 0.604
13q22.1 10 (36) 15 (44) 0.606
9p21.3 16 (57) 17 (50) 0.617
17p12 10 (36) 14 (41) 0.795
4p15.31 15 (54) 20 (59) 0.798
16q23.3 10 (36) 13 (38) 1.000
Regions with Copy Number Gains
3q26.33 4 (14) 11 (32) 0.139
19q13.2 1 (4) 3 (9) 0.620
5p15.33 2 (7) 4 (12) 0.681
8p12 4 (14) 4 (12) 1.000
11q13.3 2 (7) 3(9) 1.000
8p11.21 1 (4) 1 (3) 1.000
*p-value determined using Fisher’s exact test.
doi:10.1371/journal.pone.0030398.t003
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[34] and colorectal cancer [35]. Recent evidence in gastric cancer
suggests that SOCS6 maybe the candidate gene for the 18q22 copy
number alteration and the loss of SOCS6 appears to be a critical
genetic alteration in the development of certain subtypes of gastric
cancer [36]. The suppressor of cytokine signaling (SOCS) family
comprises eight members SOCS (1–7) and CISH. The SOCS
family of proteins negatively regulate the cytokine-induced Janus
family tyrosine kinase/signal transducers and activators of
transcription signaling pathway, thereby inhibiting the cellular
growth and proliferation of tumor cells [37]. Unlike other SOCS
family members, SOCS6 does not interact with JAK2 but has a
direct effect on the insulin receptor (IR) and KIT signaling
pathways [38,39]. The deregulation of both insulin and KIT-
signaling are known to play an important role in the proliferation
of several malignancies [40,41]. Consequently, tumor cells with
loss of SOCS6 may have increased activation of insulin and KIT-
signaling resulting in uncontrolled growth. In gastric cancer,
SOCS6 loss in conjunction with promoter hypermethylation results
in transcriptional silencing [36,42]. Here we show that SOCS6
mRNA expression is positively correlated with DNA copy number.
In our study we found a trend for increased methylation with
reduced mRNA expression in the samples with SOCS6 copy
number loss. Further study is warranted in order to better
understand the regulatory mechanisms involved in SOCS6
transcription regulation in lung SCC.
We have shown that the loss of SOCS6 copy number and
corresponding decreases in mRNA expression are related to
significantly shorter overall survival, particularly in subjects with
early stage SCC tumors. This is clinically important since a
prognostic marker for early stage SCCs is definitely needed for the
improvement of patients’ outcome. Such a prognostic marker may
allow clinicians to select the most efficacious adjuvant therapy with
consequent improvements in survival. Therefore, if our findings
are confirmed in a prospective study, SOCS6 copy number and/or
mRNA expression can be used as a molecular marker for
prediction of prognosis in patients with early stage lung SCC.
Additionally we have demonstrated that reliable screening for
SOCS6 copy number loss can be performed using the rapid and
simple method of qPCR. The small cohort size of subjects with
advanced stage SCC, limits our ability to make definitive
conclusions about the role of SOCS6 copy number and mRNA
expression as a prognostic biomarker in this cohort of subjects.
Copy number analysis can be useful to identify ‘driver’
(causative of disease) oncogenes or tumor suppressor genes [43].
Causal focal regions of gain (harboring oncogenes) and loss
Figure 2. aCGH copy number of genes within 18q22.3 demonstrating preferential loss in SCC recurrence. The Y-axis represents the
derived DNA copy number from aCGH log2 normalized data and the X-axis represents the recurrence phenotype. Mann-Whitney U test to was used
to assess for any differences in copy number between recurrence phenotypes and p values,0.05 were deemed significant.
doi:10.1371/journal.pone.0030398.g002
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e30398Figure 3. Quantitative PCR (qPCR) validation of array CGH identified candidate genes preferentially lost in SCC recurrence. The Y-
axis represents the derived DNA copy number from qPCR normalized to house-keeper genes, b-actin while the X-axis represents the DNA copy
number derived from aCGH. Pearson’s correlation coefficient was used to assess for any relationship between the copy number derived from the
methods and p values,0.05 were deemed significant. The aCGH copy number of onlySOCS6 (a) was validated by qPCR.
doi:10.1371/journal.pone.0030398.g003
Figure 4. Dot plot of qPCR-derived SOCS6 copy number (y-axis) is compared to the recurrence phenotype (x-axis) in the training
(n=62) and test set (n=72) subjects. Figure 4A and 4B represent training set and test set subjects respectively. Mann-Whitney U test to was used
to assess for any differences in copy number between recurrence phenotypes and p values,0.05 were deemed significant.
doi:10.1371/journal.pone.0030398.g004
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elucidated through high-resolution copy number analyses
[14,18,23]. These include amplifications in 1p34.2, 2p15,
3q11.2, 3q26.33, 3q29, 4q13.1, 5p15.1, 7p11.2, 8p12, 8q24.21,
9p13.3, 11q13.2, 12p12.1, 14q21.1, 19q12, 19q13.2, 20p12.3 and
22q12.2 and deletions in 3p12.3, 3q24.2, 3q12.1, 4p15.31, 4q32.1,
5p14.2, 5q31.1, 7p11.2, 8p21.3, 9p21.3, 14q21, 17p11.2 and
18q22.1 [14,18,23]. In our analysis on a platform of .40,000
elements we found gain in 3q26.33 and loss in 9p21.3 as the most
significant alterations in lung SCC, demonstrating the consistency
of results from independent studies using high-resolution aCGH
platforms. Copy number analysis has also been used to identify
genomic alterations associated with metastatic behavior of primary
lung SCC [18,24]. Yan et al. used CGH to analyze 21 non-
metastatic and 18 metastatic lung SCC tumors and found that
when taking advanced stage into consideration, gains on 2p, 20p
and losses on 2q, 4q and 18q were associated with metastases [24].
The aCGH study of Boelens et al, demonstrated that gains of 7q36,
8p12 and 10q22 were specific to SCC tumors with lymph node
metastasis, while gain of 8q22-q24 and loss of 8p23 and 13q21
were specific to SCC tumors that developed distant metastasis
within three years of surgical resection [18]. While Boelens et al.
used aCGH, they did not find an association of 18q22.3 loss with
tumor recurrence as we report here, which may reflect differences
in the study population, sample size (34 versus 62), and aCGH
platforms (6000-element bacterial artificial chromosome-based
array versus 44,000-element oligonucleotide array).
Data generated from analysis of high-throughput methods such
as aCGH needs to be validated by an alternative method such as
qPCR [44]. Inadvertent false discovery due to the large number of
probes on micoroarray platforms is the major reason for the need
to have biological validation and technical replication. In our
study, we noted differences in the aCGH-based and qPCR copy
number data. A similar lack of correlation has been noted by
others [10]. There are a number of potential reasons for this
ranging from false discovery to technical limitations, such as
differences between the microarray platform and the qPCR-based
copy number assays. For some genes it may relate to limitations of
the microarray platform. The Agilent 44B aCGH platform is a
platform with 60-mer oligonucleotide probes with resolution of
35–75 kb including coding and noncoding sequences. Low
representation of aCGH probes in some regions could prevent
Figure 5. Relationship between SOCS6 mRNA expression, copy number and recurrence phenotype. Figure 5A and 5C are scatter plots of
qRT-PCR derived SOCS6 mRNA expression (x-axis) and qPCR-derived SOCS6 copy number (y-axis) in training set (n=62) (a) and test set (n=72) (c)
respectively. Figure 5B and 5D represent SOCS6 mRNA levels (y-axis) ad recurrence phenotype (x-axis) in the training and test sets respectively.
Pearson’s correlation coefficient was used to determine any association between SOCS6 qPCR derived copy number and mRNA levels. Mann-Whitney
U test to was used to assess for any differences in copy number between recurrence phenotypes and p values,0.05 were deemed significant.
doi:10.1371/journal.pone.0030398.g005
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explanation of the poor correlation is the possibility of small
SOCS6 intra-genic copy number variations. Microdeletions within
a gene may be missed due to the resolution of this Agilent 44B
aCGH platform which has an average resolution of approximately
35–75 kb, but will be less likely by newer higher resolution,
platforms, such as the 1 M Agilent array [45,46]. Other studies
have used qPCR assays similar to those used in our study to
validate aCGH findings [47]. These qPCR assays are designed to
span the coding sequence of the candidate gene, while the aCGH
probes span both coding and non-coding sequences. Despite this,
aCGH and SNP platforms with lower resolution have been able to
provide novel insights into disease biology in solid organ
malignancies, such as ovarian cancer (50K SNP arrays) [10] and
male breast cancer (44B Agilent aCGH arrays) [48].
The tissue samples in this study were macrodissected not
microdissected. Microdissection enriches for tumor cells and
increases the ability to detect tumor-specific copy number changes.
The admixture of normal cells, infiltrating blood and lymphoid
cells in our samples may have influenced detection of copy number
alterations despite the selection of tumor samples with at least 50%
tumor cell content. Despite this limitation, our data showed that
loss of SOCS6 copy number is associated with poor prognosis. This
suggests that even despite the presence of non-tumor cells, the
detection of SOCS6 copy number alteration may have potential as
a prognostic biomarker. In this study, when we applied the
GISTIC algorithm to SCC recurrent and non-recurrent tumors
separately, we identified several genomic alterations unique to
non-recurrent tumors (5p15.33, 8q24.21, 9p21.1 and 19q13.2).
While amplifications in these regions are typically associated with
worse clinical outcome in other solid organ malignancies [49,50],
further study is warranted to understand the biological signifi-
cance, if any, of genomic alterations unique to non-recurrent
tumors in lung SCC.
Figure 6. Kaplan-Meier curves of overall survival and SOCS6 qPCR-derived copy number in study subjects with follow-up duration
of 5 years after surgical resection in the training set (n=62) and test set (n=72). Figure 6A and 6B represent overall survival in all training
set and TNM early stage subjects while 6C and 6D represent all test set and TNM early stage test set subjects. Censored values (+) indicate the last
known follow-up time for those subjects still alive after surgical resection.
doi:10.1371/journal.pone.0030398.g006
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PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30398In our study we used an array approach (Illumina BeadsArray
Technology) to screen for promoter methylation of SOCS6.W e
then used a quantitative approach (MassARRAYH EpiTYPER
analysis) to validate the methylation microarray findings. There
are now several approaches available for the study of DNA
methylation, some suited for studying single-locus methylation
[51] and others for genome-wide approaches [52]. The Illumina
BeadArray technology is appropriate technology for genome-wide
methylation analysis and the results have been validated against
methylation-sensitive PCR, a single gene locus methylation
detection method, with high analytical sensitivity [53]. On the
other hand, EpiTYPER is a highly accurate quantitative method
for that has been validated [54] and used for the evaluation of
methylation status in several malignancies including non-small cell
lung cancer [55]. Both methods demonstrated that the SOCS6
gene promoter is not hypermethylated in our samples. However,
in the tumors with low copy number of SOCS6, there was a trend
for increasing methylation, albeit non-significant. This raises the
possibility that low copy number and promoter methylation of
SOCS6 may be responsible for reduced mRNA expression.
However this will require confirmation in a larger study cohort.
In conclusion, we showed that SOCS6 located in the genomic
locus 18q22.3, has reduced gene copy number and reduced
mRNA expression in primary lung SCCs that recur early after
surgical resection. Since SOCS family proteins are known to
inhibit a potentially important growth-signaling pathway, a tumor
suppressor function in lung SCC is a possibility requiring further
study to elucidate mechanisms underlying disease recurrence.
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subjects with follow-up duration of 5 years after surgical
resection. Figure S2A represents training set subjects (n=62)
and Figure S2B represents test set subjects (n=72). Censored
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